Title
Definition of the viral targets of protective HIV-1-specific T cell responses
Date Issued
07 December 2011
Access level
open access
Resource Type
journal article
Author(s)
Mothe B.
Llano A.
Ibarrondo J.
Daniels M.
Miranda C.
Zamarreño J.
Bach V.
Zuniga R.
Pérez-Álvarez S.
Berger C.T.
Puertas M.C.
Martinez-Picado J.
Rolland M.
Farfan M.
Szinger J.J.
Hildebrand W.H.
Yang O.O.
Sanchez-Merino V.
Brumme C.J.
Brumme Z.L.
Heckerman D.
Allen T.M.
Mullins J.I.
Gómez G.
Goulder P.J.
Walker B.D.
Gatell J.M.
Clotet B.
Korber B.T.
Brander C.
Publisher(s)
Springer Nature
Abstract
Background: The efficacy of the CTL component of a future HIV-1 vaccine will depend on the induction of responses with the most potent antiviral activity and broad HLA class I restriction. However, current HIV vaccine designs are largely based on viral sequence alignments only, not incorporating experimental data on T cell function and specificity.Methods: Here, 950 untreated HIV-1 clade B or -C infected individuals were tested for responses to sets of 410 overlapping peptides (OLP) spanning the entire HIV-1 proteome. For each OLP, a "protective ratio" (PR) was calculated as the ratio of median viral loads (VL) between OLP non-responders and responders.Results: For both clades, there was a negative relationship between the PR and the entropy of the OLP sequence. There was also a significant additive effect of multiple responses to beneficial OLP. Responses to beneficial OLP were of significantly higher functional avidity than responses to non-beneficial OLP. They also had superior in-vitro antiviral activities and, importantly, were at least as predictive of individuals' viral loads than their HLA class I genotypes.Conclusions: The data thus identify immunogen sequence candidates for HIV and provide an approach for T cell immunogen design applicable to other viral infections. © 2011 Mothe et al; licensee BioMed Central Ltd.
Volume
9
Issue
1
Language
English
OCDE Knowledge area
Virología Enfermedades infecciosas
Scopus EID
2-s2.0-82755190463
PubMed ID
Source
Journal of Translational Medicine
ISSN of the container
14795876
Sponsor(s)
This work was supported by NIH contracts N01-AI-30024 and N01-AI-15422 (CB, TA, BDW, BTK, JS), NIH-NIDCR R01 DE018925-04 (CB), grant MTM2008– 06747–C02-00 (GG) from the Ministerio de Ciencia y Tecnología, a grant from the Instituto de Salud Carlos III (FIS PS09/00283, AL) and a grant from the Fundacio para la Investigacion y Prevencion del SIDA en España (FIPSE) # 360737/09, CB), Spain as well as a grant from the European Community FP7 ("CUTHIVAC”). BM holds a research fellowship grant from the FIS (Rio Hortega, CM08/00020), Madrid, Spain. ZB is supported by a New Investigator Award from the Canadian Institutes of Health Research (CIHR). CB and JMP are ICREA (Institució Catalana de Recerca i Estudis Avançats) Senior Research Professors. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Sources of information: Directorio de Producción Científica Scopus